Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Skin Diseases and Disorders01:23

Skin Diseases and Disorders

Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Reticular Dermis01:15

Reticular Dermis

The papillary and reticular dermis are the two layers of the dermis. They are made of connective tissue with fibers of collagen extending from one to the other, making the border between the two somewhat indistinct. The dermal papillae extending into the epidermis belong to the papillary layer, whereas the dense collagen fiber bundles below belong to the reticular layer.
Reticular Layer
Underlying the papillary layer is the much thicker reticular layer, composed of dense, irregular connective...
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Papillary Dermis01:11

Papillary Dermis

Dermis
The dermis might be considered the "core" of the integumentary system, as distinct from the epidermis and hypodermis. It contains blood and lymph vessels, nerves, and other structures, such as hair follicles and sweat glands. The dermis is made of two layers of connective tissue that comprise an interconnected mesh of elastin and collagenous fibers, produced by fibroblasts.
Papillary Layer
The papillary layer is made of loose, areolar connective tissue, which means the collagen and...
Healing II: Complications01:24

Healing II: Complications

Complications during healing arise when tissue repair is altered by local or systemic factors. These changes involve abnormal collagen deposition, altered biomechanics, and reduced vascular supply, impairing restoration of normal structure and function.Loss of FunctionScar tissue differs significantly from the original tissue it replaces. In the skin, fibrosis lacks adnexal structures such as hair follicles, sebaceous glands, and sweat glands. Their absence reduces tactile sensitivity, impairs...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autoantibody associations in patients with early diffuse cutaneous systemic sclerosis: the prospective registry of early systemic sclerosis.

Seminars in arthritis and rheumatism·2026
Same author

Combining Pirfenidone With Mycophenolate Mofetil for Systemic Sclerosis-Related Interstitial Lung Disease (Scleroderma Lung Study III): An Investigator-Initiated, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.

ACR open rheumatology·2025
Same author

Association of Type III and Type VI Collagen Neoepitopes With Disease Severity in Systemic Sclerosis.

The Journal of rheumatology·2025
Same author

'Am I doing this right?' Physician perceptions of the global assessment in clinical trials of systemic sclerosis.

Rheumatology (Oxford, England)·2025
Same author

Hand Swelling and Other Non-Raynaud Phenomenon Symptoms as the Initial Presentation of Systemic Sclerosis: Prevalence and Clinical Associations in Two US Cohorts.

Arthritis & rheumatology (Hoboken, N.J.)·2025
Same author

Use of Nintedanib for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease at Expert Scleroderma Centers in the United States.

Annals of the American Thoracic Society·2025
Same journal

Rheumatology at the Threshold of Artificial Intelligence.

Rheumatic diseases clinics of North America·2026
Same journal

Foreword.

Rheumatic diseases clinics of North America·2026
Same journal

Artificial Intelligence Regulation in the United States: Current Landscape and Implications for Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

The Role of Artificial Intelligence in Medical Education and Training: Implications for Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Sources of Bias in Clinical Artificial Intelligence and Applications in Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Toward Bridging the Gap from Artificial Intelligence in Clinical Research to Clinical Practice in Rheumatology: The Mayo Experience.

Rheumatic diseases clinics of North America·2026
See all related articles

Related Experiment Video

Updated: Jul 6, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

The many faces of scleroderma.

Virginia D Steen1

  • 1Department of Medicine, Georgetown University, 3800 Reservoir Road, LL Gorman, Washington, DC 20007, USA. steenv@georgetown.edu

Rheumatic Diseases Clinics of North America
|March 11, 2008
PubMed
Summary
This summary is machine-generated.

Scleroderma autoantibodies are linked to distinct patient features and prognosis. Utilizing these antibodies aids in managing scleroderma and advancing research into its causes.

More Related Videos

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus
05:39

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus

Published on: May 16, 2025

Visualizing Scar Development Using SCAD Assay - An Ex-situ Skin Scarring Assay
07:40

Visualizing Scar Development Using SCAD Assay - An Ex-situ Skin Scarring Assay

Published on: April 28, 2022

Related Experiment Videos

Last Updated: Jul 6, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus
05:39

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus

Published on: May 16, 2025

Visualizing Scar Development Using SCAD Assay - An Ex-situ Skin Scarring Assay
07:40

Visualizing Scar Development Using SCAD Assay - An Ex-situ Skin Scarring Assay

Published on: April 28, 2022

Area of Science:

  • Immunology
  • Rheumatology
  • Autoimmunity

Background:

  • Scleroderma is a complex autoimmune disease.
  • Specific autoantibodies are detected in scleroderma patients.
  • These autoantibodies correlate with disease characteristics.

Purpose of the Study:

  • To highlight the association between scleroderma autoantibodies and patient features.
  • To emphasize the utility of these antibodies in prognosis and treatment.
  • To advocate for their use in clinical trials and research.

Main Methods:

  • Analysis of demographic, clinical, and organ system data in scleroderma patients.
  • Correlation of autoantibody presence with specific disease manifestations.
  • Review of existing literature on scleroderma autoantibodies.

Main Results:

  • Scleroderma autoantibodies are associated with specific patient demographics.
  • Distinct clinical features and organ involvement correlate with autoantibody profiles.
  • Autoantibodies are linked to survival outcomes in scleroderma.

Conclusions:

  • Scleroderma autoantibodies are valuable biomarkers for predicting prognosis.
  • These antibodies can guide monitoring and treatment strategies for scleroderma.
  • Further research incorporating scleroderma autoantibodies is crucial for understanding pathogenesis.